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Abstract 
BACKGROUND: C-reactive protein (CRP) is an inflammatory marker associated with T2DM, obesity, insulin 
resistance, and cardiovascular disease.  
AIM: The present study evaluates the association of CRP +1059 G/C polymorphism of the CRP gene in 100 T2D 
cases and 100 healthy controls.  
METHODS: Present study was done by allele specific PCR method to study the CRP gene polymorphism in study 
subjects. 
RESULTS: Study found that CRP (+1059 G/C) genotype distribution among case and controls was found to be 
significant (p=0.001), Higher CRP C allele frequency (0.16) was observed compared to controls (0.04). CRP 
+1059 GC and CC had 2.72 (1.12-6.61), 20.56 (1.16-362.1) risk for T2D. It has been observed, HTN, Obesity, 
Smoking and alcoholism was found to be associated with increased risk of T2D, and a significant difference was 
observed in biochemical parameters.  
CONCLUSION: Study concluded that CRP gene polymorphism was found to be associated with risk of Type 2 
Diabetes and risk was linked with heterozygosity and mutant homozygosity. Hypertension, Obesity, Smoking and 
alcoholism increases the risk of occurrence of Type 2 Diabetes. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Type 2 diabetes mellitus (T2DM) is one of the 
major health-related global health problems [1]. 
Genetic alterations played an important role in 
determining why some diabetic patients develop these 
complications while others do not [2]. Several 
evidence showed the importance of inflammation in 
the pathogenesis of diabetic complications, especially 
enhancement of atherosclerosis and complications 
[3]. According to the International Diabetes Federation 
revealed that currently, around 415 million people with 
diabetes all over the world are likely to increase to 642 
million by 2040 [4]. T2D accounts for high morbidity 
and mortality due to complications like renal failure, 
amputations, cardiovascular disease, and 
cerebrovascular events [5]. In 2015 there were 
approximately 5.0 million deaths by diabetes 
worldwide [4]. C-reactive protein (CRP) is an 
inflammatory marker associated with T2DM, obesity, 
insulin resistance, and cardiovascular disease [6]. 
Furthermore, according to recent data, CRP is 
not an acute phase protein only, but it is a mediator of 
atherogenesis, serving as a marker for cardiovascular 
disease (CVD) [7]. CRP levels display extensive 
interindividual variability. Although plasma C reactive 
protein levels are influenced by sociodemographic, 
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behavioural, and lifestyle factors and obesity and type 
2 diabetes, twin and family studies have estimated 
that genetic factors could contribute up to 35–50% of 
the variation of CRP [8] [9]. Several population-based 
association studies have shown that common genetic 
variants at the CRP locus are significantly associated 
with plasma CRP levels [10]. CRP gene 
polymorphisms of were found to be in mild to 
moderate association with the basal CRP levels in 
healthy men and women [11].  
Thus, the current study aimed to evaluate the 
role of CRP (+1059G/C) polymorphism in type 2 
diabetic patients. 
 
 
Material and Methods 
 
The present case-control study enrolled a 
total of 200 individuals. There were 100 newly 
diagnosed type 2 diabetes and 100 healthy controls 
collected. This study was approved by the institutional 
ethical committee, Jamia Millia University. Written 
informed consent was obtained from all individual 
participants included in the study. 
All the clinical parameter such as fasting 
glucose and postprandial glucose were taken care as 
per standard criteria. Total 3 ml of blood sample were 
withdrawn, 1 collected in EDTA vials and 2 ml in plain 
vials from all the study subjects included in the study.  
DNA isolation was done by a phenol-
chloroform method from blood samples collected in 
EDTA vials from cases as well as controls. Genomic 
DNA was analysed on 1% agarose gel to confirm and 
observed under UV transilluminator. 
Isolated DNA was then amplified to determine 
the genotypes of CRP by allele-specific primers 
forward: 5′ CATTTGTACAAGCTGGGAGT 3′, 2. Allele 
C specific reverse: 5′ 
ATGGTGTTAATCTCATCTGGTGGG 3′, Allele G 
specific reverse: 
5’′TGGTGTTAATCTCATCTGGTGGC 3′ using 
thermocycler. PCR was performed in 25 μl reaction 
volume containing 3 μl of 100 ng template DNA, 0.25 
μl of 25 pmol each primer, 2.5 μl of 10 mM dNTPs, 1.5 
μl of 20mM MgCl2, 0.3 μl of 5 U/μl Taq polymerase 
with 2.5 μl of 10X Taq Buffer (Fermantas) and 14.7 μl 
of nuclease-free ddH2O. The PCR was performed with 
initial denaturation at 94°C for 10 minutes, followed by 
40 cycles of denaturation at 95°C for 40 seconds, 
annealing at 58°C for 40 seconds, extension at 72°C 
for 40 seconds and the final extension was at 72°C for 
10 minutes. The amplified product of 237 bp was 
visualised under UV transilluminator. 
Genotype frequencies between the cases and 
controls were evaluated using the Chi-square test and 
values ≤ 5 were analysed by Fisher exact test. Allele 
frequency was calculated by the Hardy–Weinberg 
Equilibrium (HWE) equation. The associations 
between CRP genotypes and risk of T2D were 
estimated by computing the odds ratios (ORs) with 
95% confidence intervals (CIs). The parametric and 
nonparametric test was used to analyse the 
quantitative data, p-value less than 0.05 considered to 
be statistically significant. 
 
 
Results 
 
Demographic characteristic of study subjects 
investigated in the present study has been 
summarised in Table 1.  
Table 1: Distribution of selected characteristics among T2D 
patients and healthy controls 
Variables T2D patients n (%) Healthy controls n (%) 
Total no. 100 (100%) 100 (100%) 
Gender 
Males 62 (62%) 64 (64%) 
Females 38 (38%) 36 (36%) 
Age at diagnosis (Years) 
≤ 50 61 (%) 66 (%) 
> 50 39 (%) 34 (%) 
Mean age (years) 49.82 47.89 
HTN 
Yes 63 (63%) 28 (28%) 
No 37 (37%) 72 (72%) 
Obesity 
Yes 20 (20%) 5 (5%) 
No 80 (80%) 95 (95%) 
Smoking status 
Yes 58 (58%) 30 (30%) 
No 42 (42%) 70 (70%) 
Alcoholism 
Yes 49 (49%) 26 (26%) 
No 51 (51%) 74 (74%) 
 
The difference observed in genotype among 
cases and controls was found to be significant (p = 
0.001) (Table 2). It was observed that high percentage 
of heterozygous GC 16 (16%) and mutant 
homozygous CC 8 (8%) genotype was found in 
patients compared to controls, heterozygous GC 8 
(8%) and CC 0 (0%) while lower GG 76 (76%) 
genotype in patients compared to control homozygous 
GG 90 (90%) genotype. The higher allele frequency of 
C allele (0.16) was observed in T2D patients 
compared to control (0.04). 
Table 2: Genotype distribution and allele frequencies of CRP 
(+1056G/C) gene among T2D patients and controls 
Variables GG n(%) GC n(%) CC n(%) p value 
Allele frequency 
G allele C allele 
Patients (n = 100) 76 (76) 16 (16) 8 (8) 0.001 0.84 0.16 
Controls (n = 100) 92 (92) 8 (8) 0 (0) 0.96 0.04 
 
Odds ratio with 95 % confidence intervals was 
calculated for each group to estimate the degree of 
association between the CRP genotype and risk of 
T2D in Indian patients depicted in Table 3. Compared 
to the GG genotype, the OR 2.72 (1.12-6.61) and 
20.56 (1.16-362.1) for the heterozygous GC and 
homozygous CC genotypes were estimated, 
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suggesting a possible dominant effect of CRP 
polymorphism on T2D risk. 
Table3: Risk of T2D associated with CRP (+1056G/C) genotype 
Genotype Healthy controls (n = 100) T2D patients (n = 100) OR (95% CI) 
GG  92 (92%) 76 (76%) (ref) 
GC 8 (8%) 16 (16%) 2.42 (0.98-5.96) 
CC 0 (0%) 8 (8%) 20.56 (1.16-362.1) 
GC+CC 8 (8%) 24 (24%) 3.63 (1.54-8.54) 
 
The risk associated with Hypertension (HTN), 
Obesity, smoking and alcoholism was calculated in 
T2D patients and depicted in (Table 4). In HTN, 
compared to the GG genotype, the OR 1.52 (0.47-
4.79), 4.82 (0.56-41.20) for the heterozygous GC and 
homozygous CC genotypes. In obesity, compared to 
the GG genotype, the OR 1.61 (0.44-5.80) and 2.90 
(0.61-13.72) for the heterozygous GA and 
homozygous AA genotypes. Patients with smoking, 
alcoholism status compared to the GG genotype, the 
OR for GC 1.87 (0.59-5.92), 3.02 (0.95-9.56) and for 
CC 2.56 (0.48-13.51), 4.12 (0.78-21.79) respectively.  
Table 4: Risk of CRP genotype in T2D patients associated with 
different variables 
Genotype HTN No (n = 37) HTN Yes (63) OR* (95% CI) 
GG  31 45 (ref) 
GC 5 11 1.51 (0.47-4.79) 
CC 1 7 4.82 (0.56-41.20) 
Genotype Obesity No (n = 80) Obesity Yes (n = 20) OR* (95% CI) 
GG  63 13 (ref) 
GC 12 4 1.61 (0.44-5.80) 
CC 5 3 2.90 (0.61-13.72) 
Genotype Smoker No (n=42) Smoker Yes (n=58) OR* (95% CI) 
GG  35 41 (ref) 
GC 5 11 1.87 (0.59-5.92) 
CC 2 6 2.56 (0.48-13.51) 
Genotype Alcohol No (n=49) Alcohol Yes (n=51) OR* (95% CI) 
GG  32 44 (ref) 
GC 11 5 3.02 (0.95-9.56) 
CC 6 2 4.12 (0.78-21.79) 
 
Other serum markers such as cholesterol, 
TG, LDL, VLDL, HDL, serum uric acid, bilirubin total, 
fasting blood glucose and postprandial glucose were 
compared between T2D patients, and healthy controls 
were shown in table 6. High lipid parameter such as 
TG, LDL, VLDL and were observed higher in T2D 
patients compared to controls and the differences was 
found to be significant (p < 0.0001, p < 0.0001, p < 
0.0001), however no significant difference was 
observed in cholesterol level among T2D cases and 
controls (p = 0.73). Serum uric acid and total bilirubin 
were observed to be high compared to healthy control 
group (p < 0.0001, p < 0.0001). High fasting and 
postprandial blood glucose were observed in T2D 
cases compared to healthy controls, and the 
difference was found to be significant (p < 0.0001, p < 
0.0001). 
Table 5: Serum markers level of T2D patients and healthy 
controls 
Serum markers T2D patients 
(Mean + SD) 
Healthy controls 
(Mean + SD) 
p-value 
Cholesterol 206.8 ± 43.02 205.2 ± 19.05 0.73 
TG  183.3 ± 42.62 139.5 ± 24.92 <0.0001 
LDL  147.4 ± 28.77 113.3 ± 14.10 <0.0001 
VLDL 34.16 ± 5.62 25.32 ± 4.81 <0.0001 
Serum uric acid 5.44 ± 1.85 4.20 ± 0.74 <0.0001 
Bilirubin total 0.86 ± 0.44 0.64 ± 0.20 0.0003 
Fasting blood sugar 171.1 ± 39.55 92.75 ± 10.88 <0.0001 
Postprandial blood sugar 257.7 ± 51.94 126.7 ± 9.58 <0.0001 
Patients and controls with different risk factor 
were analysed to see the effect on biochemical 
parameters, and it was observed that the patients and 
controls had hypertension history had a significant 
impact on biochemical parameters. T2D patients with 
HTN history had elevated level of TG, LDL, VLDL, 
Serum uric acid, bilirubin, fasting blood sugar and 
postprandial blood sugar compared to healthy control 
with HTN history. In the same way, others risk factors 
were found to affect most of the biochemical 
parameters and found to be significant. 
Table 6: Effect of different risk factor positive on serum 
markers level among T2D patients and healthy controls 
HTN history yes In T2D Healthy control p-value 
Cholesterol 208.3 ± 43.49 210.2 ± 17.95 0.82 
TG 182.8 ± 43.10 138 ± 23.67 < 0.0001 
LDL 138.9 ± 27.19 118.4 ± 15.54 0.0003 
VLDL 34.62 ± 5.74 26.32 ± 3.78 < 0.0001 
Serum uric acid 5.51 ± 1.73 4.26 ± 0.59 < 0.0001 
Bilirubin total 0.83 ± 0.43 0.67 ± 0.20 0.23 
Fasting blood sugar 174.8 ± 42.39 92.54 ± 11.66 < 0.0001 
Postprandial blood sugar 256.2 ± 54.99 127.1 ± 1.60 < 0.0001 
Obesity history yes In T2D Healthy control p-value 
Cholesterol 207.6 ± 45.59 208 ± 27.16 0.98 
TG 194.4 ± 47.36 174.8 ± 49.06 0.42 
LDL 140 ± 27.69 109.2 ± 12.66 0.02 
VLDL 33.80 ± 5.55 23.60 ± 4.27 0.0009 
Serum uric acid 5.41 ± 1.51 4.02 ± 0.73 0.009 
Bilirubin total 0.68 ± 0.33 0.78 ± 0.16 0.16 
Fasting blood sugar 167.1 ± 31.61 93.0 ± 11.90 < 0.0001 
Postprandial blood sugar 251.5 ± 56.60 128.8 ± 10.03 < 0.0001 
Alcoholism history yes In T2D Healthy control p-value 
Cholesterol 210.7 ± 45.08 201.6 ± 18.35 0.33 
TG 191.1 ± 44.13 136.0 ± 14.46 < 0.0001 
LDL 139.1 ± 28 117.2 ± 14.20 0.0004 
VLDL 34.22 ± 5.46 24.81 ± 4.36 < 0.0001 
Serum uric acid 5.75 ± 2.05 4.19 ± 0.87 0.0004 
Bilirubin total 0.87 ± 0.44 0.68 ± 0.20 0.08 
Fasting blood sugar 180.4 ± 46.93 93.42 + 11.73 < 0.0001 
Postprandial blood sugar 262.6 ± 55.92 123.3 ± 9.04 < 0.0001 
Smoking history yes In T2D Healthy control p-value 
Cholesterol 208.2 ± 42.54 203.5 ± 20.04 0.56 
TG 185.8 ± 48.01 136.3 ± 24.74 < 0.0001 
LDL 139.4 ± 29.59 113.1 ± 12.85 < 0.0001 
VLDL 35.09 ± 6.06 25.0 ± 4.08 < 0.0001 
Serum uric acid 5.44 ± 1.73 4.23 ± 0.92 0.0002 
Bilirubin total 0.82 ± 0.39 0.66 ± 0.21 0.03 
Fasting blood sugar 173.7 ± 42.02 92.0 ± 10.86 < 0.0001 
Postprandial blood sugar 261.1 ± 57.51 128.3 ± 8.92 < 0.0001 
 
 
 
Discussion 
 
Identification of the genetic determinants 
could facilitate the risk prediction of disease 
development and the implementation of individualised 
treatment for therapy. Up to now, genome-wide 
association studies (GWAS) for diabetes have 
identified more than 80 susceptibility loci, but only a 
small part of the heritability of diabetes can be 
explained by those findings [12]. In the present study 
we observed a significant difference in the distribution 
of CRP genotype among T2D case and healthy 
controls, higher mutant allele distribution was 
observed among T2D cases compared to healthy 
controls. An independent association of mutant CC 
genotype and GC heterozygous genotype of CRP 
gene were found to be associated with increased risk 
of T2D.  
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It was observed that the CC and GC genotype 
in patients showed more than 20 and 2 fold increase 
risk of T2D compared to healthy controls. Patients 
with different status like hypertension (HTN), doing 
alcoholism showed more than 4 fold increased the risk 
of T2D with mutant CC genotypes of the CRP gene. 
However, obesity, smoking had mutant CC genotypes 
of CRP gene showed more than 2 fold higher risk of 
T2D. Hypertension, alcoholism, obesity and smoking 
behaviour are suggestive to a possible risk factor for 
developing T2D. It has been observed that several 
lipid parameters such as TG, LDL, and VLDL were 
found to be elevated in T2D cases compared to 
healthy controls.  
Serum uric acid and total bilirubin were found 
to elevated in T2D compared to healthy controls as 
the basal values of CRP appear to be significantly 
heritable [13]. D. Thalmaier et al. found that 
polymorphisms in the CRP gene and in genes 
controlling CRP expression influence CRP levels and 
CRP (+1059G/C) polymorphism involved in the same 
way [14]. It has been observed that +1059 G/C 
(rs1800947) nucleotide polymorphism (SNP) in exon 2 
of the CRP gene. +1059G/C is a synonymous 
polymorphism, which has been reported to affect the 
protein levels of CRP and contribute to the 
progression of CAD (coronary artery disease) and 
T2D [15].  
Hypertension is recognised globally as a 
major risk factor for CVD, stroke, diabetes, and renal 
diseases [16]. Several studies have shown that most 
of the hypertensive patients have significant instability 
of serum lipid parameters in hypertensive patients [17, 
18]. Smoking may be linked to impaired glucose and 
lipid metabolism, and a wealth of evidence indicates 
that insulin resistance, abnormal glucose and lipid 
metabolism [19]. Parchwani DN et al. reported that 
glucose and altered lipid profile are directly found to 
be correlated with smoking and length of smoking 
years [20], and Haggard also reported that smoking 
even a single could be the cause of increased blood 
sugar [21]. 
It has been suggested moderate alcohol 
intake increases the risk of type 2 diabetes, 
especially in Japanese lean subjects [22]. 
Considering facts that East Asian subjects with 
normal BMI level (< 25 kg/m
2
) can easily develop 
type 2 diabetes [23], and large differences in the 
polymorphic distribution of alcohol-metabolizing 
enzymes have been reported between East Asian 
and Caucasian, the effects of alcohol intake on type 
2 diabetes might vary according to ethnicity [24]. 
The study concluded that CRP gene 
polymorphism was found to be associated with risk of 
Type 2 Diabetes and risk was linked with 
heterozygosity and mutant homozygosity. 
Hypertension, Obesity, Smoking and 
alcoholism significantly altered biochemical 
parameters in Type 2 Diabetes patients. These 
interesting results of the study deserve further 
validation on a larger population. 
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